Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

2.

No socioeconomic inequalities in colorectal cancer survival within a randomised clinical trial.

Nur U, Rachet B, Parmar MK, Sydes MR, Cooper N, Lepage C, Northover JM, James R, Coleman MP; AXIS collaborators.

Br J Cancer. 2008 Dec 2;99(11):1923-8. doi: 10.1038/sj.bjc.6604743. Epub 2008 Oct 28.

Supplemental Content

Loading ...
Support Center